ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to outsmart mutating breast cancer
Disease control OngoingThis study is for people with advanced, hormone-driven breast cancer that has developed a specific gene mutation (ESR1) while on standard treatment. It tests if switching from a common type of hormone pill (an aromatase inhibitor) to a new experimental pill (AZD9833), while keepi…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for advanced breast cancer patients in major global trial
Disease control OngoingThis large Phase 3 trial is testing whether a new oral drug called camizestrant (AZD9833) works better than the current standard treatment when both are combined with palbociclib. The study involves 1,370 people with advanced ER-positive, HER2-negative breast cancer who haven't r…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC